Briefing
Alpha-CORRECT: surveillance ctDNA positivity was strongly associated with recurrence in stage III colorectal cancer
In the observational alpha-CORRECT cohort of 124 patients with stage III colorectal cancer presented at ASCO GI 2025, a tumor-informed assay using up to 200 variants found that ctDNA positivity during surveillance was associated with recurrence (HR 49.6; 95% CI 16.6 to 148.3), with a median lead time of 10.4 months before a clinical diagnosis of recurrence.